Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients. Here, FASLG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.